Accession Number

Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)

DrugDrug Description
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
OritavancinAn antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
BleomycinA chemotherapy agent used to treat various malignancies, including head and neck malignancy, lymphoma, and testicular tumors, among others.
VancomycinA glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections.
TU-514Not Available
PhosphoramidonNot Available
BalhimycinBalhimycin is a novel glycopeptide antibiotic.
SulfatideAny of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers and may accumulate in metachromatic leukodystrophy.
LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
CefilavancinInvestigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.
TeicoplaninA glycopeptide antibiotic with a similar mechanism of action and spectrum of activity to vancomycin used to treat various infections caused by gram-positive bacteria.
DalbavancinAn antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria.
TelavancinAn antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia.
UlinastatinUlinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
KRN-7000KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients...
SiagosideSiagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a...
RivipanselRivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
Bleomycin A6Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug...
Ceramide NPCeramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3...
Ceramide APNot Annotated
Ceramide NGNot Annotated
UproleselanUproleselan is under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
ABX-196ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).
Drugs & Drug Targets
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastaseenzyme
OritavancinCytochrome P450 3A4enzyme
OritavancinCytochrome P450 2D6enzyme
OritavancinCytochrome P450 2C9enzyme
OritavancinCytochrome P450 2C19enzyme
OritavancinSerum albumincarrier
OritavancinPeptidoglycan precursorstarget
OritavancinBacterial cell wall peptide bridging segmentstarget
OritavancinPentaglycyl bridging segmenttarget
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
BleomycinDNA ligase 3target
BleomycinDNA ligase 1target
BleomycinBleomycin hydrolaseenzyme
VancomycinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
VancomycinSerum albumincarrier
Vancomycinalpha1-acid glycoproteincarrier
VancomycinHistamine H1 receptorcarrier
TU-514UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylasetarget
PhosphoramidonKell blood group glycoproteintarget
LJP 1082Beta-2-glycoprotein 1target
TeicoplaninD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DalbavancinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
NaxitamabGD2 disialogangliosidetarget